Institution
Ikerbasque
Other•Bilbao, Spain•
About: Ikerbasque is a other organization based out in Bilbao, Spain. It is known for research contribution in the topics: Graphene & Quantum. The organization has 713 authors who have published 7967 publications receiving 231990 citations. The organization is also known as: Basque Foundation for Science.
Topics: Graphene, Quantum, Population, Galaxy, Magnetization
Papers published on a yearly basis
Papers
More filters
University of British Columbia1, National Autonomous University of Mexico2, Arizona State University3, National University of Cordoba4, University of Oxford5, University of Vermont6, Helmholtz Centre for Environmental Research - UFZ7, Charles Sturt University8, Lüneburg University9, Oregon State University10, Georgia Institute of Technology11, University of Kiel12, Ikerbasque13, University of Victoria14
TL;DR: It is proposed that focusing only on instrumental or intrinsic values may fail to resonate with views on personal and collective well-being, or “what is right,” with regard to nature and the environment, and it is time to engage seriously with a third class of values, one with diverse roots and current expressions: relational values.
Abstract: A cornerstone of environmental policy is the debate over protecting nature for humans’ sake (instrumental values) or for nature’s (intrinsic values) (1). We propose that focusing only on instrumental or intrinsic values may fail to resonate with views on personal and collective well-being, or “what is right,” with regard to nature and the environment. Without complementary attention to other ways that value is expressed and realized by people, such a focus may inadvertently promote worldviews at odds with fair and desirable futures. It is time to engage seriously with a third class of values, one with diverse roots and current expressions: relational values. By doing so, we reframe the discussion about environmental protection, and open the door to new, potentially more productive policy approaches.
977 citations
Paracelsus Private Medical University of Salzburg1, University of Duisburg-Essen2, Semmelweis University3, University of Turin4, Institut Gustave Roussy5, Brown University6, Pontifical Catholic University of Chile7, University of Barcelona8, Trinity College, Dublin9, Istituto Superiore di Sanità10, Ikerbasque11, Pohang University of Science and Technology12, University of Louisville13, Ghent University Hospital14, La Trobe University15, Harvard University16, National University of Singapore17, Maastricht University18, University of Mainz19, University of Cambridge20, Utrecht University21, Agency for Science, Technology and Research22, University of Gothenburg23, University of Valencia24, University of Freiburg25, Aalborg University26, National Research Council27, Paul Ehrlich Institute28, German Red Cross29, University of Oxford30, Karolinska Institutet31
TL;DR: In this paper, the authors summarize recent developments and the current knowledge of extracellular vesicles (EVs) and discuss safety and regulatory requirements that must be considered for pharmaceutical manufacturing and clinical application.
Abstract: Extracellular vesicles (EVs), such as exosomes and microvesicles, are released by different cell types and participate in physiological and pathophysiological processes. EVs mediate intercellular communication as cell-derived extracellular signalling organelles that transmit specific information from their cell of origin to their target cells. As a result of these properties, EVs of defined cell types may serve as novel tools for various therapeutic approaches, including (a) anti-tumour therapy, (b) pathogen vaccination, (c) immune-modulatory and regenerative therapies and (d) drug delivery. The translation of EVs into clinical therapies requires the categorization of EV-based therapeutics in compliance with existing regulatory frameworks. As the classification defines subsequent requirements for manufacturing, quality control and clinical investigation, it is of major importance to define whether EVs are considered the active drug components or primarily serve as drug delivery vehicles. For an effective and particularly safe translation of EV-based therapies into clinical practice, a high level of cooperation between researchers, clinicians and competent authorities is essential. In this position statement, basic and clinical scientists, as members of the International Society for Extracellular Vesicles (ISEV) and of the European Cooperation in Science and Technology (COST) program of the European Union, namely European Network on Microvesicles and Exosomes in Health and Disease (ME-HaD), summarize recent developments and the current knowledge of EV-based therapies. Aspects of safety and regulatory requirements that must be considered for pharmaceutical manufacturing and clinical application are highlighted. Production and quality control processes are discussed. Strategies to promote the therapeutic application of EVs in future clinical studies are addressed.
954 citations
TL;DR: Evidence is summarized that molecular pathways characterized in pathology are also utilized by microglia in the normal and developing brain to influence synaptic development and connectivity, and therefore should become targets of future research.
946 citations
TL;DR: In this paper, the use of oleylamine (OAm) as a versatile reagent for the synthesis of various nanoparticle systems is discussed, including the ability of OAm to act as a surfactant, solvent, and reducing agent, as a function of other synthesis parameters.
Abstract: Wet chemistry in organic solvents has proven highly efficient for the preparation of several types of metallic, metal-oxide, and semiconductor nanostructures. This Short Review focuses on the use of oleylamine (OAm) as a versatile reagent for the synthesis of various nanoparticle systems. We describe the ability of OAm to act as a surfactant, solvent, and reducing agent, as a function of other synthesis parameters. We also discuss the specific role of OAm either alone or in combination with other reactants, to form nanostructures using a variety of organic or inorganic compounds as precursors. In certain cases OAm can form complex compounds with the metal ions of the corresponding precursor, leading to metastable compounds that can act as secondary precursors and thus be decomposed in a controlled way to yield nanoparticles. We also point out that OAm-stabilized particles can often be dispersed in different organic solvents yielding solutions with enhanced colloidal stability over long times and the poten...
933 citations
University of Marburg1, University of Erlangen-Nuremberg2, Rovira i Virgili University3, University of Göttingen4, Max Planck Society5, University of California, Los Angeles6, International School for Advanced Studies7, University of Melbourne8, University of Trieste9, Ikerbasque10, University of Toronto11, Nanyang Technological University12, National Institutes of Health13, Stanford University14, Shanghai Jiao Tong University15, Tongji University16, University of Seville17, Karolinska Institutet18, Drexel University19, Sichuan University20, Rice University21, Northwestern University22, University of Basel23, Zhejiang University24, Heidelberg University25, University of Tokyo26, Harvard University27, University of Utah28, University of Michigan29, Swiss Federal Laboratories for Materials Science and Technology30, Seoul National University31, Saarland University32, Columbia University33, Chinese Academy of Sciences34, Kazan Federal University35, Emory University36, University of California, Irvine37, Autonomous University of Barcelona38, University of Massachusetts Amherst39, Pennsylvania State University40, Ghent University41, Imperial College London42, National Tsing Hua University43, South China University of Technology44, University of Ulm45, Hebrew University of Jerusalem46, Huazhong University of Science and Technology47, Peking University48
TL;DR: An overview of recent developments in nanomedicine is provided and the current challenges and upcoming opportunities for the field are highlighted and translation to the clinic is highlighted.
Abstract: The design and use of materials in the nanoscale size range for addressing medical and health-related issues continues to receive increasing interest. Research in nanomedicine spans a multitude of areas, including drug delivery, vaccine development, antibacterial, diagnosis and imaging tools, wearable devices, implants, high-throughput screening platforms, etc. using biological, nonbiological, biomimetic, or hybrid materials. Many of these developments are starting to be translated into viable clinical products. Here, we provide an overview of recent developments in nanomedicine and highlight the current challenges and upcoming opportunities for the field and translation to the clinic.
926 citations
Authors
Showing all 775 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Luis M. Liz-Marzán | 132 | 616 | 61684 |
| Maurizio Prato | 109 | 741 | 63055 |
| Francisco Guinea | 108 | 573 | 69426 |
| Rafael Yuste | 104 | 342 | 37415 |
| Tom Broadhurst | 96 | 422 | 30074 |
| Alexei Verkhratsky | 89 | 450 | 29788 |
| Maria Forsyth | 84 | 749 | 33340 |
| J. Garay Garcia | 81 | 348 | 23275 |
| Ángel Borja | 77 | 316 | 20302 |
| Wei Zhang | 76 | 1932 | 34966 |
| Mirko Prato | 76 | 370 | 21189 |
| Nate Bastian | 76 | 355 | 18342 |
| A. J. Castro-Tirado | 72 | 728 | 24272 |
| Rainer Hillenbrand | 71 | 227 | 18259 |
| B. Andrei Bernevig | 69 | 280 | 29935 |